Antiverse Secures £3.5 Million Funding for Growth
Antiverse, a pioneering techbio company specializing in the design of antibodies for challenging targets, has made a significant announcement regarding an increase in its funding. On October 15, 2024, the Cardiff, Wales-based firm disclosed that it had successfully added £3.5 million ($4.6 million) to its seed funding round, bringing the total equity financing raised to an impressive £7.2 million ($10.1 million). This latest investment round was led by the prominent i&i Biotech Fund I (i&i Bio) and Kadmos Capital, with existing investors including InnoSpark Ventures, UKI2S (managed by Future Planet Capital), Tensor Ventures, and AngelHub also contributing. This funding boost will propel the company's growth, including hiring talented individuals and advancing its antibody design programs, many of which are being developed in collaboration with leading pharmaceutical companies.
The influx of capital will primarily be directed towards expanding the company’s laboratory and machine learning teams.
This initiative aims to enhance the development of Antiverse’s internal assets, particularly those targeting G-protein-coupled receptors (GPCRs) and ion channels, as they move towards clinical trials. Additionally, the company intends to improve its predictive accuracy within its antibody design platform by focusing on the curation of training data. To further solidify its position in the biotech landscape, Antiverse has inaugurated new facilities in cities such as Boston, Massachusetts, and Prague, Czech Republic, expanding its operational capacity to deliver on a promising pipeline of projects.
Utilizing a machine-learning-centered approach for antibody design, Antiverse is addressing significant challenges in bringing essential therapies to market. The company's platform employs ‘target-specific libraries’ crafted from structural and sequence data to generate high-confidence libraries against specific targets, thus boosting predictive accuracy compared to conventional antibody libraries. This innovative strategy accelerates the antibody discovery process to just six months. As Murat Tunaboylu, Co-Founder and CEO of Antiverse, noted, the company is on the cusp of making GPCRs and other difficult targets druggable, which could ultimately lead to better therapies for patients globally. With backing from investors like John Gebeily of Kadmos Capital, who recognizes the potential impact of the AI-driven antibody design platform, Antiverse is well-positioned to revolutionize the pharmaceutical industry and contribute significantly to advancing healthcare.
They've invested in Antiverse
Get to know these Biotech investors
| Investor | Sector | Stage | Activity | Team | Connect |
|---|---|---|---|---|---|
 i&i Biotech Fund I (i&i Bio) | 1 investment investment | more info | |||
 Kadmos Capital | 12 investments investments | 2 contacts contacts | |||
 InnoSpark Ventures | 3 investments investments | more info | |||
 UKI2S | 14 investments investments | 3 contacts contacts | |||
 Future Planet Capital | 10 investments investments | 11 contacts contacts | |||
 Tensor Ventures | 8 investments investments | 5 contacts contacts | |||
 UKI2S (managed by Future Planet Capital) | 1 investment investment | more info |
Click here for a full list of 7,589+ startup investors in the UK